文献速递肝病消化道肿瘤与早癌

抗病毒治疗后慢性丙型肝炎患者肝外恶性肿瘤风险:台湾T-COACH全国真实世界研究

Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH).
PubMed 文献 · Am J Gastroenterol · 2020-01-01

基于台湾T-COACH全国真实世界队列10,714例接受干扰素为基础治疗的慢性丙型肝炎患者,中位随访3.79年,评估获得持续病毒学应答(SVR)对12种肝外恶性肿瘤风险的影响。结果显示SVR并未降低总体肝外恶性肿瘤发生率,但与非SVR相比,SVR与胃癌和非霍奇金淋巴瘤风险显著降低相关,且该效应仅在<65岁患者中观察到。

要点

  • SVR未降低总体肝外恶性肿瘤年发生率(0.69% vs 0.87%)。
  • 非SVR者胃癌和非霍奇金淋巴瘤风险显著高于SVR者。
  • SVR降低胃癌和非霍奇金淋巴瘤风险仅见于<65岁患者。

核心结论

  • HCV根除可降低胃癌和非霍奇金淋巴瘤风险,尤其在年轻患者中,提示慢性丙型肝炎应尽早治疗。

研究设计与样本

  • 台湾T-COACH全国真实世界队列纳入10,714例接受干扰素为基础治疗的慢性丙型肝炎患者(8,186例SVR,2,528例非SVR),链接国家癌症登记数据库,中位随访3.79年(范围0-16.44年)。

主要发现

  • 随访44,354人年期间,324例(3.02%)发生肝外恶性肿瘤,SVR与非SVR患者间无差异(年发生率0.69% vs 0.87%)。
  • 非SVR者胃癌年发生率显著高于SVR者(0.10% vs 0.03%/人年,P=0.004)。
  • 非SVR者非霍奇金淋巴瘤年发生率显著高于SVR者(0.08% vs 0.03%/人年,P=0.03)。
  • 以死亡为竞争风险时,非SVR独立与胃癌相关(HR 3.29,95%CI 1.37-7.93,P=0.008)。
  • 按年龄分层,SVR降低胃癌(HR 0.30,95%CI 0.11-0.83)和非霍奇金淋巴瘤(HR 0.28,95%CI 0.09-0.85)风险仅见于<65岁患者。

临床怎么用

  • 对慢性丙型肝炎患者应尽早启动抗病毒治疗以追求SVR,尤其<65岁患者可能更多获益于降低胃癌和非霍奇金淋巴瘤风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Chronic hepatitis C virus (HCV) infection is associated with nonhepatocellular carcinoma malignancies. We aimed to evaluate whether achieving a sustained virological response (SVR, defined as HCV RNA seronegativity throughout posttreatment 24-week follow-up) could reduce the risk of non-hepatocellular carcinoma malignancy in a real-world nationwide Taiwanese Chronic Hepatitis C Cohort (T-COACH). METHODS: A total of 10,714 patients with chronic hepatitis C who had received interferon-based therapy (8,186 SVR and 2,528 non-SVR) enrolled in T-COACH and were linked to the National Cancer Registry database for the development of 12 extrahepatic malignancies, including those with potential associations with HCV and with the top-ranking incidence in Taiwan, over a median follow-up period was 3.79 years (range, 0-16.44 years). RESULTS: During the 44,354 person-years of follow-up, 324 (3.02%) patients developed extrahepatic malignancies, without a difference between patients with and without SVR (annual incidence: 0.69% vs 0.87%, respectively). Compared with patients with SVR, patients without SVR had a significantly higher risk of gastric cancer (0.10% vs 0.03% per person-year, P = 0.004) and non-Hodgkin lymphoma (NHL) (0.08% vs 0.03% per person-year, respectively, P = 0.03). When considering death as a competing risk, non-SVR was independently associated with gastric cancer (hazard ratio [HR]/95% confidence intervals [CIs]: 3.29/1.37-7.93, P = 0.008). When patients were stratified by age, the effect of SVR in reducing gastric cancer (HR/CI: 0.30/0.11-0.83) and NHL (HR/CI: 0.28/0.09-0.85) was noted only in patients aged <65 years but not those aged >65 years. DISCUSSION: HCV eradication reduced the risk of gastric cancer and NHL, in particular among younger patients, indicating that patients with chronic hepatitis C should be treated as early as possible.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Huang CF, Lai HC, Chen CY, et al. Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). Am J Gastroenterol. 2020. PMID: 32221162. doi:10.14309/ajg.0000000000000606

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。